Colorectal cancer (CRC) is the third most common cancer worldwide. 1 Whereas SMAD4 and TP53 inactivating mutations are very frequent in human colon cancer, with mutation rates of 14% and 64%, respectively (www.cbiop ortal.org), it has not been fully elucidated whether and how they interact in colorectal carcinogenesis. Therefore,